Cyclophosphamide (CP) is an anticancer drug, an alkylating agent. Cardiotoxicity of CP is
associated with one of its metabolites, acrolein, and clinical cardiotoxicity manifestations are …

In vitro screening for potential side effects of drugs on human-induced pluripotent stem-cell-
derived cardiomyocytes (hiPSC-CMs) is a cutting-edge technology in pharmaceutical …

Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold great
promise for studying inherited cardiac arrhythmias and developing drug therapies to treat …

Introduction Cardiotoxicity assessment using human induced pluripotent stem cell-derived
cardiomyocytes (iPSC-CMs) forms a key component of the Comprehensive in Vitro …

Cardiac side-effects are one of the major reasons for failure of drugs during preclinical
development. Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have been …

Abstract Introduction The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative
proposes a three-step approach to evaluate proarrhythmogenic liability of drug candidates …

To assess the utility of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-
CMs) as an in vitro proarrhythmia model, we evaluated the concentration dependence and …

Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) hold promise for
assessment of drug-induced arrhythmias and are being considered for use under the …

Human induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs) provide a novel
assay system to assess cardiac safety in drug development to overcome a problem of …

Fulfilling the potential of human induced pluripotent stem cell (hiPSC)-derived
cardiomyocytes for studying conduction and arrhythmogenesis requires development of …